{
  "id": 19808243,
  "title": "Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.",
  "url": "https://urgent.news/2026/11/13/exelixis-has-2-major-catalysts-coming-by-march-2027-heres-what-19808243",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T12:25:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/exelixis-has-2-major-catalysts-coming-march-2027-heres-what-investors-should-watch"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsExelixis’ cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.",
        "url": "https://urgent.news/2026/11/13/exelixis-has-2-major-catalysts-coming-by-march-2027-heres-what",
        "published": "2026-11-13T12:05:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}